Home › Funds › Bellevue Group AG › EPRX
Bellevue Group AG position in EPRX
EUPRAXIA PHARMACEUTICALS INC · Health Care
Bellevue Group AG reported holding 2,595,139 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$23.6M, representing 0.49% of its reported portfolio and ranking #46 among its reported holdings. Bellevue Group AG first reported this position in Q3 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's EPRX position evolved
Bellevue Group AG first disclosed a stake in EPRX in Q3 2026 at 2,595,139 shares (US$23.6M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 2.60M | $23.62M | New |
About EPRX and 13F data
EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 72 other funds we track also report a position in EPRX — the largest reported positions include Affinity Asset Advisors, LLC (US$15.6M), Vivo Capital, LLC (US$12.3M), GREAT POINT PARTNERS LLC (US$10.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- Affinity Asset Advisors, LLC 1.72M sh · $15.62M · Q3 2026
- Vivo Capital, LLC 1.35M sh · $12.29M · Q3 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $10.92M · Q3 2026
- Caligan Partners LP 1.16M sh · $10.58M · Q3 2026
- PFM Health Sciences, LP 1.13M sh · $10.26M · Q3 2026
- Ikarian Capital, LLC 809.74K sh · $7.37M · Q3 2026
- Seven Fleet Capital Management LP 572.27K sh · $5.21M · Q3 2026
- Redmile Group, LLC 519.88K sh · $4.73M · Q3 2026
- DAFNA Capital Management LLC 404.57K sh · $3.68M · Q3 2026
- Velan Capital Investment Management LP 352.00K sh · $3.20M · Q3 2026
- Aisling Capital Management LP 325.00K sh · $2.96M · Q3 2026
- DV EQUITIES, LLC 276.00K sh · $2.51M · Q3 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held EPRX?
Bellevue Group AG has disclosed EPRX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Bellevue Group AG's current position in EPRX?
As of Q3 2026, Bellevue Group AG holds 2.60M shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $23.62M, representing 0.49% of its reported portfolio and ranking #46.
Has Bellevue Group AG been buying or selling EPRX?
In the latest 13F filing (Q3 2026), Bellevue Group AG newly opened its position in EPRX.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Affinity Asset Advisors, LLC, Vivo Capital, LLC, GREAT POINT PARTNERS LLC, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.